Posts by Joy Tsai, MD
-
After Denosumab Discontinuation, Alendronate Superior to Raloxifene at Maintaining BMD Gains
Massachusetts General Hospital researchers found that for postmenopausal women with osteoporosis who discontinue short-term denosumab treatment and are unable or unwilling to transition to a bisphosphonate, raloxifene may be a suitable alternative, although inferior in maintaining the gain in bone mineral density.
Biography
Joy Tsai, MD, is an endocrinologist and physician-investigator in the Endocrinology Division at Massachusetts General Hospital and an assistant professor of Medicine at Harvard Medical School.
Endocrinology Division
The Endocrinology Division at Massachusetts General Hospital offers a comprehensive integrated program of clinical services for both primary and tertiary care of adults with endocrine disorders.